UNLABELLED: Typically, hepatitis B virus (HBV) decays in patients under therapy in a biphasic manner. However, more complex decay profiles of HBV DNA (e.g., flat partial response, triphasic, and stepwise), for which we have no clear understanding, have also been observed in some treated patients. We recently introduced the notion of a critical drug efficacy, epsilon(c), such that if overall drug efficacy, epsilon(tot), is higher than the critical drug efficacy (i.e., epsilon(tot) > epsilon(c)) then viral levels will continually decline on therapy, while if epsilon(tot) < epsilon(c), then viral loads will initially decline but will ultimately stabilize at a new set point, as seen in flat partial responders. Using the idea of critical efficacy and including hepatocyte proliferation in a viral kinetic model, we can account for these complex HBV DNA decay profiles. The model predicts that complex profiles such as those exhibiting a plateau or shoulder phase, as well as a class of stepwise declines, occur only in patients in whom the majority of hepatocytes are infected before therapy. CONCLUSION: We show via kinetic modeling how a variety of HBV DNA decay profiles can arise in treated patients.
UNLABELLED: Typically, hepatitis B virus (HBV) decays in patients under therapy in a biphasic manner. However, more complex decay profiles of HBV DNA (e.g., flat partial response, triphasic, and stepwise), for which we have no clear understanding, have also been observed in some treated patients. We recently introduced the notion of a critical drug efficacy, epsilon(c), such that if overall drug efficacy, epsilon(tot), is higher than the critical drug efficacy (i.e., epsilon(tot) > epsilon(c)) then viral levels will continually decline on therapy, while if epsilon(tot) < epsilon(c), then viral loads will initially decline but will ultimately stabilize at a new set point, as seen in flat partial responders. Using the idea of critical efficacy and including hepatocyte proliferation in a viral kinetic model, we can account for these complex HBV DNA decay profiles. The model predicts that complex profiles such as those exhibiting a plateau or shoulder phase, as well as a class of stepwise declines, occur only in patients in whom the majority of hepatocytes are infected before therapy. CONCLUSION: We show via kinetic modeling how a variety of HBV DNA decay profiles can arise in treated patients.
Authors: Harel Dahari; Marian Major; Xinan Zhang; Kathleen Mihalik; Charles M Rice; Alan S Perelson; Stephen M Feinstone; Avidan U Neumann Journal: Gastroenterology Date: 2005-04 Impact factor: 22.682
Authors: N D Theise; M Nimmakayalu; R Gardner; P B Illei; G Morgan; L Teperman; O Henegariu; D S Krause Journal: Hepatology Date: 2000-07 Impact factor: 17.425
Authors: Stanca M Ciupe; Ruy M Ribeiro; Patrick W Nelson; Geoffrey Dusheiko; Alan S Perelson Journal: Proc Natl Acad Sci U S A Date: 2007-03-14 Impact factor: 11.205
Authors: Joshua T Schiffer; Martine Aubert; Nicholas D Weber; Esther Mintzer; Daniel Stone; Keith R Jerome Journal: J Virol Date: 2012-06-20 Impact factor: 5.103
Authors: Jeremie Guedj; Yaron Rotman; Scott J Cotler; Christopher Koh; Peter Schmid; Jeff Albrecht; Vanessa Haynes-Williams; T Jake Liang; Jay H Hoofnagle; Theo Heller; Harel Dahari Journal: Hepatology Date: 2014-10-27 Impact factor: 17.425